Dannce.ai, a provider of a digital movement disorder assessment platform for clinicians and drug developers, raised $2.6 million in Pre-Seed funding.
LDV Capital led the investment round with participation from Glasswing Ventures, The Leo Lion Company, Duke Capital Partners, and Merck Digital Sciences Studio.
With new funds, Dannce.ai intends to further advance the capabilities of its AI-enabled digital phenotyping platform that allows clinicians and drug developers to perform motion analysis on patients with neurological conditions. The video-based platform aims to help characterize treatment responses and improve neurological care.
In the official statement, Rob Baldoni, CEO and co-founder of dannce.ai, stated: “One in ten individuals will be diagnosed with a movement disorder during their lifetime. We are creating a world where aging adults have broad access to objective neurological screenings and new therapies for these disorders are also objectively validated,”
“We have brought together a powerhouse team with Tim and Jesse, two of the world’s leading experts in behavioral quantification, Shereen Shermak, our COO, and Joe Chan, our CTO, who have an extensive track record of scaling ventures and building products. We will be the first to provide clinicians and drug developers with a solution that characterizes drug effects and optimizes neurological care.”